Business
Envoy Medical Reports Third Quarter 2025 Financial and Operational Results
Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent portfolio; In addition, subsequent to quarter end, the Company received FDA approval to expand its pivotal clinical trial to the final stage, restarted enrollment, and successfully raised additional capitalWhite Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy...
About this update from Envoy Medical, Inc.
[{"type":"text","content":"Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent portfolio; In addition, subsequent to quarter end, the Company received FDA approval to expand its pivotal clinical trial to the final stage, restarted enrollment, and successfully raised additional capital","length":385,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"White Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the third quarter ended September 30, 2025, as well as other subsequent events.","length":365,"tagName":"p"},{"type":"text","content":"Corporate Highlights for Third Quarter 2025:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Extinguished over $32 Million in Debt, Strengthening Balance Sheet","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced Commercialization Planning as FDA Clinical Trial Remains On Track","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded Patent Portfolio by Securing Additional European Patent ","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured Four New Global Patents","length":31,"tagName":"p"}]},{"val":[{"type":"text","content":"Successfully Reached Three-Month Follow-Up Milestone in Clinical Trial ","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured an Additional Three New Patents","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"Further Expanded Patent Portfolio with New Issuances in the United States","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":417,"olType":false},{"type":"text","content":"Subsequent to Third Quarter 2025 End","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced Closing of Up to $16 Million Registered Direct Offering Priced At-the-Mark...